Amy Tilley

1.0k total citations
5 papers, 444 citations indexed

About

Amy Tilley is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Amy Tilley has authored 5 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Amy Tilley's work include HER2/EGFR in Cancer Research (4 papers), Advanced Breast Cancer Therapies (2 papers) and Cancer Treatment and Pharmacology (2 papers). Amy Tilley is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Advanced Breast Cancer Therapies (2 papers) and Cancer Treatment and Pharmacology (2 papers). Amy Tilley collaborates with scholars based in United States. Amy Tilley's co-authors include Richard Pazdur, Amna Ibrahim, Shenghui Tang, Robert Justice, Laleh Amiri‐Kordestani, Suparna Wedam, Patricia Cortazar, Lijun Zhang, Rajeshwari Sridhara and Todd R. Palmby and has published in prestigious journals such as Clinical Cancer Research.

In The Last Decade

Amy Tilley

5 papers receiving 438 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Tilley United States	5	309	207	111	106	96	5	444
Jennifer Foglietta Italy	10	283 0.9×	162 0.8×	66 0.6×	108 1.0×	65 0.7×	20	413
Stefania Kinspergher Italy	12	227 0.7×	318 1.5×	52 0.5×	97 0.9×	112 1.2×	36	428
A. Barnadas Spain	10	244 0.8×	88 0.4×	84 0.8×	179 1.7×	83 0.9×	27	419
Ilana Schlam United States	11	324 1.0×	142 0.7×	116 1.0×	162 1.5×	93 1.0×	41	535
Neelima Vidula United States	16	476 1.5×	321 1.6×	89 0.8×	177 1.7×	196 2.0×	67	719
Fernando Ortiz-Martínez Spain	9	220 0.7×	77 0.4×	78 0.7×	221 2.1×	120 1.3×	12	419
Douglas Robinson United States	8	236 0.8×	196 0.9×	63 0.6×	255 2.4×	110 1.1×	15	481
Wei-Dong Wei China	9	188 0.6×	184 0.9×	72 0.6×	134 1.3×	121 1.3×	12	419
Shin Takayama Japan	10	246 0.8×	109 0.5×	48 0.4×	163 1.5×	148 1.5×	37	497
Tanja Badovinac-Črnjević United States	7	418 1.4×	161 0.8×	185 1.7×	68 0.6×	120 1.3×	9	533

Countries citing papers authored by Amy Tilley

Since Specialization

Citations

This map shows the geographic impact of Amy Tilley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Tilley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Tilley more than expected).

Fields of papers citing papers by Amy Tilley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Tilley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Tilley. The network helps show where Amy Tilley may publish in the future.

Co-authorship network of co-authors of Amy Tilley

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Tilley. A scholar is included among the top collaborators of Amy Tilley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Tilley. Amy Tilley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Shah, Anand, Erik Bloomquist, Shenghui Tang, et al.. (2018). FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research. 24(13). 2999–3004. 88 indexed citations

2.

Walker, Amanda J., Suparna Wedam, Laleh Amiri‐Kordestani, et al.. (2016). FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research. 22(20). 4968–4972. 104 indexed citations

3.

Amiri‐Kordestani, Laleh, Suparna Wedam, Lijun Zhang, et al.. (2014). First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer. Clinical Cancer Research. 20(21). 5359–5364. 114 indexed citations

4.

Kluetz, Paul G., Yang‐Min Ning, V. Ellen Maher, et al.. (2013). Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary. Clinical Cancer Research. 19(24). 6650–6656. 49 indexed citations

5.

Blumenthal, Gideon M., Nancy S. Scher, Patricia Cortazar, et al.. (2013). First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research. 19(18). 4911–4916. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact